Buchheidt Dieter, Böhme Angelika, Cornely Oliver A, Fätkenheuer Gerd, Fuhr Heinz-Georg, Heussel Gudula, Junghanss Christian, Karthaus Meinolf, Kellner Olaf, Kern Winfried V, Schiel Xaver, Sezer Orhan, Südhoff Thomas, Szelényi Hubert
III. Medizinische Klinik, Universitätsklinikum Mannheim, Ruprecht-Karls-Universität Heidelberg, Wiesbadener Strasse 7-11, 68305, Mannheim, Germany.
Ann Hematol. 2003 Oct;82 Suppl 2:S127-32. doi: 10.1007/s00277-003-0766-2. Epub 2003 Sep 9.
Approximately 85% of patients with acute leukemia undergoing intensive antileukemic treatment develop infections and/or fever during neutropenic phases; in about 50% of these patients clinical, microbiological or clinical and microbiological evidence of infections can be obtained. The response rate is significantly lower in documented infections than in fever of unknown origin (FUO). Evidence-based recommendations for diagnosis and treatment procedures are presented, reflecting study results and expert opinions.
接受强化抗白血病治疗的急性白血病患者中,约85%在中性粒细胞减少期会发生感染和/或发热;在这些患者中,约50%可获得感染的临床、微生物学或临床及微生物学证据。有记录的感染患者的缓解率明显低于不明原因发热(FUO)患者。本文提出了基于证据的诊断和治疗程序建议,反映了研究结果和专家意见。